Literature DB >> 14965363

Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer.

Hideki Kataoka1, Hisaki Igarashi, Masao Kanamori, Megumi Ihara, Jian-Dong Wang, You-Jie Wang, Zhong-You Li, Takahiro Shimamura, Toshihiko Kobayashi, Keiji Maruyama, Toshio Nakamura, Hajime Arai, Masayoshi Kajimura, Hiroyuki Hanai, Masamitsu Tanaka, Haruhiko Sugimura.   

Abstract

Evidence suggests that the erythropoietin-producing hepatocellular (EPH) receptor tyrosine kinases (RTKs) and their ephrin (EFN) ligands are involved in human carcinogenesis. Expression of two of them, EFNA1 ligand and its receptor, EPHA2, has been proposed to contribute to tumor-induced neovascularization. Colorectal cancers were examined for expressions of EPHA2 and its ligand EFNA1 by semi-quantitative RT-PCR, and double-immunostained for EPHA2 and CD34. Microvessels in the tumors were counted. Double-staining was also performed in 25 cases of adenoma with focal cancer for comparison. Trends of overexpression of both EPHA2 and EFNA1 was found in tumor tissue compared to the corresponding normal tissue in the same specimen [22/37 (59.5%) and 25/37 (67.5%), respectively; P = 0.100 for EPHA2 and P = 0.009 for EFNA1]. Overexpression of EPHA2 and EFNA1 was noted more frequently in the early stage than in the late stage [EPHA2, 15/21 (71.4%) vs. 7/16 (43.8%), P = 0.007; EFNA1, 15/21 (71.4%) vs. 10/16 (62.5%), P = 0.007]. Both EPHA2 and EFNA1 were more frequently overexpressed in smaller tumors (less than 5 cm) than in larger tumors [EPHA2, 15/21 (71.4%) vs. 7/16 (43.8%), P = 0.017; EFNA1, 16/21 (76.2%) vs. 8/16 (50%), P = 0.001]. Tumors less than 5 cm in diameter and in stages I and II were significantly more likely to overexpress EPHA2 and EFNA1 (P = 0.001 for EPHA2, P = 0.001 for EFNA1). Microvessel counts (MVCs) after immunostaining for CD34 were significantly correlated (r = 0.343, P = 0.037) with overexpression of EPHA2. EPHA2-expressing focal cancer also surrounded microvessels in adenomas with focal cancers. These findings suggest an involvement of EPHA2 in colon carcinogenesis, mainly in stages I and II, and probably through their effect on microvessel induction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14965363     DOI: 10.1111/j.1349-7006.2004.tb03194.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  42 in total

1.  Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice.

Authors:  Weibo Cai; Alireza Ebrahimnejad; Kai Chen; Qizhen Cao; Zi-Bo Li; David A Tice; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-03       Impact factor: 9.236

Review 2.  Regulation and misregulation of Eph/ephrin expression.

Authors:  Dina N Arvanitis; Alice Davy
Journal:  Cell Adh Migr       Date:  2012-03-01       Impact factor: 3.405

3.  Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.

Authors:  Masato Nishimura; Eun-Jung Jung; Maitri Y Shah; Chunhua Lu; Riccardo Spizzo; Masayoshi Shimizu; Hee Dong Han; Cristina Ivan; Simona Rossi; Xinna Zhang; Milena S Nicoloso; Sherry Y Wu; Maria Ines Almeida; Justin Bottsford-Miller; Chad V Pecot; Behrouz Zand; Koji Matsuo; Mian M Shahzad; Nicholas B Jennings; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Anil K Sood; George A Calin
Journal:  Cancer Discov       Date:  2013-09-03       Impact factor: 39.397

4.  Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor.

Authors:  Carla M Lema Tomé; Enzo Palma; Sara Ferluga; W Todd Lowther; Roy Hantgan; Jill Wykosky; Waldemar Debinski
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

Review 5.  The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Authors:  Jill Wykosky; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

6.  Epigenetic silencing of HOPX promotes cancer progression in colorectal cancer.

Authors:  Hiroshi Katoh; Keishi Yamashita; Mina Waraya; Ofer Margalit; Akira Ooki; Hideaki Tamaki; Hiroyuki Sakagami; Kenichi Kokubo; David Sidransky; Masahiko Watanabe
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

7.  EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.

Authors:  Philip D Dunne; Sonali Dasgupta; Patrick G Johnston; Sandra Van Schaeybroeck; Jaine K Blayney; Darragh G McArt; Keara L Redmond; Jessica-Anne Weir; Conor A Bradley; Takehiko Sasazuki; Senji Shirasawa; Tingting Wang; Supriya Srivastava; Chee Wee Ong; Ken Arthur; Manuel Salto-Tellez; Richard H Wilson
Journal:  Clin Cancer Res       Date:  2015-08-17       Impact factor: 12.531

8.  Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer.

Authors:  Helenia Ansuini; Annalisa Meola; Zeynep Gunes; Valentina Paradisi; Monica Pezzanera; Stefano Acali; Claudia Santini; Alessandra Luzzago; Federica Mori; Domenico Lazzaro; Gennaro Ciliberto; Alfredo Nicosia; Nicola La Monica; Alessandra Vitelli
Journal:  J Oncol       Date:  2010-01-14       Impact factor: 4.375

9.  Targeted delivery of paclitaxel to EphA2-expressing cancer cells.

Authors:  Si Wang; Roberta Noberini; John L Stebbins; Swadesh Das; Ziming Zhang; Bainan Wu; Sayantan Mitra; Sandrine Billet; Ana Fernandez; Neil A Bhowmick; Shinichi Kitada; Elena B Pasquale; Paul B Fisher; Maurizio Pellecchia
Journal:  Clin Cancer Res       Date:  2012-11-15       Impact factor: 12.531

10.  Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival.

Authors:  N I Herath; J Doecke; M D Spanevello; B A Leggett; A W Boyd
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.